Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis-Reference-Cited by-同舟云学术

Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis

Published:2021-06-01 Issue:6 Volume:78 Page:699
ISSN:2168-6149
Container-title:JAMA Neurology
language:en
Short-container-title:JAMA Neurol

Author:

Salter Amber¹,Fox Robert J.²,Newsome Scott D.³,Halper June⁴,Li David K. B.⁵,Kanellis Pamela⁶,Costello Kathleen⁷,Bebo Bruce⁷,Rammohan Kottil⁸,Cutter Gary R.⁹,Cross Anne H.¹

Affiliation:

1. Washington University School of Medicine in St Louis, St Louis, Missouri

2. Cleveland Clinic, Cleveland, Ohio

3. Johns Hopkins University School of Medicine, Baltimore, Maryland

4. Consortium of MS Centers, Hackensack, New Jersey

5. The University of British Columbia, Vancouver, British Columbia, Canada

6. MS Society of Canada, Toronto, Ontario, Canada

7. National Multiple Sclerosis Society, Chicago, Illinois

8. University of Miami School of Medicine, Miami, Florida

9. The University of Alabama at Birmingham, Birmingham

Publisher

American Medical Association (AMA)

Subject

Clinical Neurology

Link

https://jamanetwork.com/journals/jamaneurology/articlepdf/2777735/jamaneurology_salter_2021_oi_210015_1622672586.64882.pdf

Reference29 articles.

1. An Italian programme for COVID-19 infection in multiple sclerosis.;Sormani;Lancet Neurol,2020

2. COVID-19 in people with multiple sclerosis: a global data sharing initiative.;Peeters;Mult Scler,2020

3. The prevalence of MS in the United States: a population-based estimate using health claims data.;Wallin;Neurology,2019

4. Clinical characteristics of coronavirus disease 2019 in China.;Guan;N Engl J Med,2020

5. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019: United States, February 12-March 28, 2020.;Chow;MMWR Morb Mortal Wkly Rep,2020

Cited by 242 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disease-modifying therapies, outcomes, risk factors and severity of COVID-19 in multiple sclerosis: A MENACTRIMS registry based study;Multiple Sclerosis and Related Disorders;2024-10

2. Does dosing frequency of anti‐CD20 therapies blunt vaccine responses and increase COVID‐19 susceptibility in patients with multiple sclerosis?;British Journal of Clinical Pharmacology;2024-09-08

3. Hospitalisations and humoral COVID-19 vaccine response in vaccinated rituximab-treated multiple sclerosis patients;Multiple Sclerosis and Related Disorders;2024-09

4. COVID-19 and multiple sclerosis: challenges and lessons for patient care;The Lancet Regional Health - Europe;2024-09

5. Switching disease-modifying therapies from sphingosine-1-phosphate receptor modulators to natalizumab or dimethyl fumarate restores immune responses after SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis;Clinical Neurology and Neurosurgery;2024-08